← 返回

通过深度学习识别免疫浸润以评估肝细胞癌患者的预后

英文原题:Identifying immune infiltration by deep learning to assess the prognosis of patients with hepatocellular carcinoma.

查看英文原题

Identifying immune infiltration by deep learning to assess the prognosis of patients with hepatocellular carcinoma.

PubMed 2023/07/14(内容时间) J Cancer Res Clin Oncol Q2 · IF 3.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们构建并测试了一个深度学习模型,用于评估 HCC 患者肝癌组织中的免疫浸润。我们的研究结果证明了该模型在评估患者预后、免疫浸润和免疫检查点表达水平方面的价值。

研究思路结论见上方概要

肝细胞癌的治疗形势依然严峻。利用深度学习算法评估免疫浸润是一种有前景的新型诊断工具。

获取了西京医院(XJH)队列和TCGA队列的患者数据和全切片图像(WSIs)。我们使用Visual studio 2022以C#语言编写程序,将WSI分割成小块。病理学家对这些小块进行分类,随后通过ML.NET使用TensorFlow框架,以ResNet 101V2网络训练深度学习模型。使用AccuracyMicro与AccuracyMacro评估模型性能。使用ROC曲线与PR曲线检查模型性能。使用R包survminer计算免疫浸润百分比以计算组间截断值,并使用Kaplan Meier方法绘制患者的总生存曲线。使用Cox回归确定免疫浸润百分比是否为预后的独立危险因素。构建列线图,并使用时间依赖性ROC曲线与校准曲线验证其准确性。使用CIBERSORT算法评估组间免疫浸润。使用基因本体探索差异表达基因的通路。

训练集包含100个WSI和165,293个tile。最终深度学习模型的AccuracyMicro为97.46%,AccuracyMacro为82.28%。训练集和验证集上ROC曲线的AUC均超过0.95。分类PR曲线下面积均超过0.85,但验证集上TLS的PR曲线下面积除外,其可能因样本过少而结果较差(0.713)。TIL分类组之间的OS存在显著差异(p < 0.001),而TLS组之间的OS无显著差异(p = 0.294)。Cox回归显示,TIL百分比是HCC患者预后的独立危险因素(p = 0.015)。根据列线图,TCGA队列中1年、2年和5年的AUC分别为0.714、0.690和0.676,XJH队列中分别为0.756、0.797和0.883。两组样本之间七种免疫细胞类型的浸润水平存在显著差异,基因本体论显示,两组之间的差异表达基因与免疫相关。其PD-1和CTLA4的表达水平也存在显著差异。

展开英文摘要原文

The treatment situation for hepatocellular carcinoma remains critical. The use of deep learning algorithms to assess immune infiltration is a promising new diagnostic tool.

Patient data and whole slide images (WSIs) were obtained for the Xijing Hospital (XJH) cohort and TCGA cohort. We wrote programs using Visual studio 2022 with C# language to segment the WSI into tiles. Pathologists classified the tiles and later trained deep learning models using the ResNet 101V2 network via ML.NET with the TensorFlow framework. Model performance was evaluated using AccuracyMicro versus AccuracyMacro. Model performance was examined using ROC curves versus PR curves. The percentage of immune infiltration was calculated using the R package survminer to calculate the intergroup cutoff, and the Kaplan Meier method was used to plot the overall survival curve of patients. Cox regression was used to determine whether the percentage of immune infiltration was an independent risk factor for prognosis. A nomogram was constructed, and its accuracy was verified using time-dependent ROC curves with calibration curves. The CIBERSORT algorithm was used to assess immune infiltration between groups. Gene Ontology was used to explore the pathways of differentially expressed genes.

There were 100 WSIs and 165,293 tiles in the training set. The final deep learning models had an AccuracyMicro of 97.46% and an AccuracyMacro of 82.28%. The AUCs of the ROC curves on both the training and validation sets exceeded 0.95. The areas under the classification PR curves exceeded 0.85, except that of the TLS on the validation set, which might have had poor results (0.713) due to too few samples. There was a significant difference in OS between the TIL classification groups (p < 0.001), while there was no significant difference in OS between the TLS groups (p = 0.294). Cox regression showed that TIL percentage was an independent risk factor for prognosis in HCC patients (p = 0.015). The AUCs according to the nomogram were 0.714, 0.690, and 0.676 for the 1-year, 2-year, and 5-year AUCs in the TCGA cohort and 0.756, 0.797, and 0.883 in the XJH cohort, respectively. There were significant differences in the levels of infiltration of seven immune cell types between the two groups of samples, and gene ontology showed that the differentially expressed genes between the groups were immune related. Their expression levels of PD-1 and CTLA4 were also significantly different.

We constructed and tested a deep learning model that evaluates the immune infiltration of liver cancer tissue in HCC patients. Our findings demonstrate the value of the model in assessing patient prognosis, immune infiltration and immune checkpoint expression levels.

论文信息

作者
Jia W、Shi W、Yao Q、Mao Z、Chen C、Fan A、Wang Y、Zhao Z
第一作者单位
Xi'an Medical University, Xi'an, China.China
通讯作者单位
Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China. wjsong@fmmu.edu.cn.China
期刊
Journal of cancer research and clinical oncology2023 Nov
原文标识
PubMed 37450030 · DOI 10.1007/s00432-023-05097-z